CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 426 enrolled
Drug / intervention
LEO 90100 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01866163
NCT01866163Phase 3Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

LEO Pharma·interventional·Posted May 31, 2013·Updated Mar 10, 2025

In Brief

A Phase 3 clinical trial evaluating LEO 90100 and Vehicle for Psoriasis Vulgaris. Completed, enrolled 426 participants across 1 site.

Detailed Summary

The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 31, 2013
Enrollment StartJun 1, 2013
Primary CompletionOct 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.1 years ago

Interventions

LEO 90100drug

Vehicledrug